From Mode of Action to Resistance Mechanisms

Samir Mouhssine,Nawar Maher,Bassam Francis Matti,Alaa Fadhil Alwan,Gianluca Gaidano

DOI: https://doi.org/10.3390/ijms25063234

IF: 5.6

2024-03-13

International Journal of Molecular Sciences

Abstract:The B cell receptor (BCR) signaling pathway plays a crucial role in B cell development and contributes to the pathogenesis of B cell neoplasms. In B cell malignancies, the BCR is constitutively active through both ligand-dependent and ligand-independent mechanisms, resulting in continuous Bruton tyrosine kinase (BTK) signaling activation, which provides a survival and proliferation advantage to the neoplastic clone. Among B cell malignancies, those in which the most significant results were obtained by treatment with BTK inhibitors (BTKi) include chronic lymphocytic leukemia, mantle cell lymphoma, lymphoplasmacytic lymphoma, and diffuse large B cell lymphoma. Covalent BTKi (namely ibrutinib, acalabrutinib, and zanubrutinib) functions by irreversibly blocking BTK through covalent binding to the cysteine residue 481 (Cys-481) in the ATP-binding domain. Despite the high efficacy and safety of BTKi treatment, a significant fraction of patients affected by B cell malignancies who are treated with these drugs experience disease relapse. Several mechanisms of resistance to covalent BTKi, including Cys-481 mutations of BTK, have been investigated in B cell malignancies. Non-covalent BTKi, such as pirtobrutinib, have been developed and proven effective in patients carrying both Cys-481-mutated and unmutated BTK. Moreover, targeting BTK with proteolysis-targeting chimeras (PROTACs) represents a promising strategy to overcome resistance to BTKi in B cell neoplasms.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper primarily explores the mechanisms of action and resistance mechanisms of targeting Bruton tyrosine kinase (BTK) in B-cell malignancies. Specifically, the paper focuses on the following types of B-cell malignancies:

1. **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)**: BTK inhibitors (such as Ibrutinib) have significantly improved the progression-free survival and overall survival of CLL patients.
2. **Mantle Cell Lymphoma (MCL)**: BTK inhibitors like Ibrutinib and Zanubrutinib have shown significant efficacy in the treatment of MCL.
3. **Lymphoplasmacytic Lymphoma (LPL)**: BTK inhibitors such as Ibrutinib and Zanubrutinib have demonstrated good therapeutic effects on LPL.
4. **Diffuse Large B-Cell Lymphoma (DLBCL)**: Particularly the activated B-cell-like subtype (ABC-DLBCL), where BTK inhibitors have shown certain efficacy.

The paper also discusses in detail the mechanisms of BTK inhibitors, including how they irreversibly block BTK activity by covalently binding to the Cys-481 site. Additionally, the study points out the issue of resistance to BTK inhibitors in clinical applications, including BTK gene mutations (such as Cys-481 mutations), PLC γ2 gene mutations, and other genetic alterations that may lead to drug failure.

In summary, the paper aims to summarize the mechanisms of action and resistance mechanisms of BTK inhibitors in B-cell malignancies and provides directions for future research.